Jolanda Howe Biography and Net Worth

Jolanda Howe is the SVP of Mirum Pharmaceuticals.

What is Jolanda Howe's net worth?: The estimated net worth of Jolanda Howe is at least $224,041.48 as of March 17th, 2025. Howe owns 4,841 shares of Mirum Pharmaceuticals stock worth more than $224,041 as of March 26th. This net worth approximation does not reflect any other assets that Howe may own. Learn More about Jolanda Howe's net worth.
How do I contact Jolanda Howe?: The corporate mailing address for Howe and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at ir@mirumpharma.com. Learn More on Jolanda Howe's contact information.
Has Jolanda Howe been buying or selling shares of Mirum Pharmaceuticals?: Within the last three months, Jolanda Howe has sold $2,681,471.02 of Mirum Pharmaceuticals stock. Most recently, Jolanda Howe sold 57,606 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a transaction totalling $2,554,826.10. Following the completion of the sale, the senior vice president now directly owns 4,841 shares of the company's stock, valued at $214,698.35. Learn More on Jolanda Howe's trading history.
Who are Mirum Pharmaceuticals' active insiders?: Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?: During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 3,680 shares worth more than $124,300.35. During the last twelve months, insiders at the sold shares 17 times. They sold a total of 172,113 shares worth more than $7,304,987.14. The most recent insider tranaction occured on March, 17th when SVP Jolanda Howe sold 57,606 shares worth more than $2,554,826.10. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.
Information on this page was last updated on 3/17/2025.

Jolanda Howe Insider Trading History at Mirum Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2025	Sell	57,606	$44.35	$2,554,826.10	4,841
2/3/2025	Sell	1,064	$48.22	$51,306.08	4,232
1/24/2025	Sell	902	$47.92	$43,223.84	3,524
1/7/2025	Sell	750	$42.82	$32,115.00	2,926
11/14/2024	Sell	2,500	$47.10	$117,750.00	2,426
7/2/2024	Sell	375	$34.00	$12,750.00	2,426
2/2/2024	Sell	735	$26.19	$19,249.65	1,759
1/8/2024	Sell	528	$28.04	$14,805.12	722
12/5/2023	Sell	2,500	$32.40	$81,000.00
8/25/2023	Sell	3,459	$26.23	$90,729.57
7/3/2023	Sell	915	$25.65	$23,469.75	3,459

Jolanda Howe Buying and Selling Activity at Mirum Pharmaceuticals

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Today's Range

Now: $46.28

$45.83

$47.20

50 Day Range

MA: $48.02

$43.01

$53.16

2 Week Range

Now: $46.28

$23.14

$54.23

Volume

393,047 shs

Average Volume

509,454 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04